Home » Open Orphan (ORPH) » Irish Independent – Open Orphan subsidiary starts testing drug for treating Covid-19

Irish Independent – Open Orphan subsidiary starts testing drug for treating Covid-19

by Ellie Donnelly

A subsidiary of Open Orphan has started testing a drug that could potentially treat Covid-19.

Open Orphan is a Europe- focused pharma services company specialising in rare disease and so-called orphan drugs.

The tests are being carried out by its London-based subsidiary Hvivo on behalf of its client Nearmedic International.

The drug being tested has both potential anti-viral and anti-inflammatory activity, and therefore could reduce both virus infectivity and disease severity respectively, a statement from Open Orphan said.

Hvivo will be testing its utility against a panel of viruses that include influenza virus, “normal”, circulating betacoronavirus and ultimately SARS-CoV2 (Covid-19).

Cathal Friel, chairman of Open Orphan, said: “We are very happy to be assisting in the battle against Covid-19 and are delighted to be working with Nearmedic International.”

“Hvivo is a world leading provider of services to global vaccine and antiviral development companies and our scientists have considerable knowledge from previous anti-viral trials which gives us confidence in our testing,” he added

Link here for original article

Leave a comment

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.